Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy

31. oktober 2026 opdateret af: Tao Zhang

An Open-Label, Single-Arm, Single-Center Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Refractory to ≥2 Prior Lines of Chemotherapy

This study aims to evaluate the efficacy and safety of TAS-102 combined with nedaplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma who have experienced disease progression after two or more lines of prior chemotherapy.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

36

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age: 18-75 years;

  2. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

  3. Diagnosis: Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction;

  4. Prior Treatment: Disease progression or failure after receiving second-line or later chemotherapy;

  5. TNM Stage: TNM Stage IV (TanyNanyM1);

  6. Measurable Disease: Presence of at least one radiologically evaluable lesion per RECIST v1.1 criteria (or other applicable criteria) within 21 days prior to enrollment;

  7. Adequate Organ Function: Defined as follows within specified timeframes before enrollment;

    • Hematology:

      • Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L
      • Platelet count (PLT) ≥ 90 × 10⁹/L
      • Hemoglobin (Hb) ≥ 90 g/L
    • Biochemistry:

      • Total Bilirubin (TBIL) ≤ Upper Limit of Normal (ULN)
      • Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 1.5 × ULN
      • Alkaline Phosphatase (ALP) ≤ 2.5 × ULN
      • Blood Urea Nitrogen (BUN) and Serum Creatinine (Cr) ≤ 1.5 × ULN
      • Creatinine Clearance (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
    • Coagulation:

      • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN
      • Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN
    • Cardiac Function:

      • Left Ventricular Ejection Fraction (LVEF) ≥ 55% as measured by Echocardiography (ECHO) or Multigated Acquisition Scan (MUGA)
      • Corrected QT interval using Fridericia's formula (QTcF) < 470 ms for females and < 450 ms for males on Electrocardiogram (ECG);
  8. Informed Consent: Voluntarily provide written informed consent prior to any study-specific procedures.

Exclusion Criteria:

  1. Prior TAS-102: Previous treatment with TAS-102;

  2. Concurrent Anticancer Therapy: Concurrent participation in another clinical trial involving anticancer therapy;

  3. Recent Major Surgery: Undergone major surgical procedures within 4 weeks prior to enrollment, or has not fully recovered from such procedures;

  4. Significant Cardiac Disease: History or presence of clinically significant cardiac disease, including but not limited to:

    • History of congestive heart failure (CHF) or systolic dysfunction (LVEF < 50%).
    • High-risk uncontrolled arrhythmias, significant ventricular arrhythmia (e.g., ventricular tachycardia), or high-grade atrioventricular block.
    • Angina pectoris requiring anti-anginal medication.
    • Clinically significant valvular heart disease.
    • ECG evidence of transmural myocardial infarction.
    • Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg);
  5. General Exclusion: Any other condition that, in the judgment of the Investigator, would make the subject unsuitable for participation in the study or compromise protocol compliance.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: TAS-102 plus nedaplatin

TAS-102:35mg/m2(BID, D1-5, D8-12)Q4W, 6 cycles + Nedaplatin:80-100mg/m2 Q4W, 6 cycles

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: Through out the study (up to 2 years)

The efficacy of solid tumors was evaluated according to RECIST v1.1

Through out the study (up to 2 years)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective response rate (ORR)
Tidsramme: Through out the study (up to 2 years)

The efficacy of solid tumors was evaluated according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1).

Through out the study (up to 2 years)
Disease control rate (DCR)
Tidsramme: Through out the study (up to 2 years)

The efficacy of solid tumors was evaluated according to RECIST v1.1

Through out the study (up to 2 years)
Overall survival (OS)
Tidsramme: Through out the study (up to 2 years)

The efficacy of solid tumors was evaluated according to RECIST v1.1

Through out the study (up to 2 years)
Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)
Tidsramme: Through out the study (up to 2 years)

Adverse events will be assessed by investigator(s) according to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0).

Through out the study (up to 2 years)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

2. august 2025

Først indsendt, der opfyldte QC-kriterier

31. oktober 2026

Først opslået (Faktiske)

3. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

31. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TAS-102-GAS

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .